Skip to Main Content

Paper Details

Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol
0
2022
AR, CRPC, Prostate cancer, androgen, androgen receptor, apalutamide, cancer, darolutamide, enzalutamide, men, nonmetastatic castration-resistant prostate cancer, patient, patients, prostate-specific antigen, testosterone
Author NameAffiliation
Matthew B RettigInstitute of Urologic Oncology, David Geffen School of Medicine at university of california los angeles
Matthew B RettigVA Greater Los Angeles Healthcare System
Himisha BeltranDana Farber Cancer Institute, Harvard Medical School
Himisha BeltranDana Farber Cancer Institute, Harvard Medical School
William K OhTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 5

Datasets

Release 1.2